Can amylin-only weight-loss drugs work without GLP-1?
Two adult trials show weight loss with amylin drugs used alone. Different timelines and ways of reporting nausea complicate a comparison.
Search explainers, questions, and medicine profiles.
Every published article, newest first. Reporting, explainers, and practical guides on weight and metabolic health.
Two adult trials show weight loss with amylin drugs used alone. Different timelines and ways of reporting nausea complicate a comparison.
The two groups ended at similar BMIs. The surgery group started higher, and the Ozempic group excluded people who stopped early.
A new review puts flavor in focus. Two small studies and the Wegovy label tell different parts of the story.
A report of depersonalization and derealization raises a question about the medicine that larger studies of depression and suicidality leave open.
The TriNetX analysis concerns adults with artery disease and no diabetes; its findings do not establish equal cardiovascular protection.
The findings concern established MASH with liver scarring, not general eligibility for weight-loss treatment.
The 25.4% headline belongs to a selected group. Delayed responders, missing observations and dose escalation explain why the distinction matters.
A closer look at questionnaire changes, the people included, and why pills and injections cannot be ranked from these data.
The one-year combination results separate joint response from weight loss, with important limits around discontinuation and exploratory testing.